The 7th Annual "Accelerating Research & Treatments for Castleman Disease" Working Dinner Meeting, an ancillary meeting to the American Society of Hematology Annual Meeting, will take place on Saturday, December 1, 2018 in San Diego, CA from 7:30-9:30pm at the Hard Rock Hotel, across the street from the San Diego Convention Center. A "Drinks and Data" poster session showcasing research related to Castleman disease will be held from 6:30-7:30pm at the same location prior to the Working Dinner Meeting.
All physicians and/or researchers interested in or currently treating or studying Castleman disease are invited to attend! Please take a couple minutes to let us know that you plan to attend by completing the following registration form.
If you would like to submit a poster abstract for consideration at the "Drinks and Data" poster session from 6:30-7:30pm, please complete the abstract submission form by November 1, 2018.
Beginning at 7:30PM, we will have dinner and review the most up to date research, discuss important issues for patient care, and come up with an action plan for 2019.
Each annual working dinner has been an amazing opportunity for the international community of Castleman disease physicians and researchers to come together to discuss key CDCN priorities focused on patient care and the international research agenda. The CDCN is looking forward to continuing the conversation and pushing forward in our efforts to defeat Castleman disease this year!
Saturday, December 1, 2018
9:30 - 11:00AM: ASH General Education Session: "Anxiety-Provoking Consults: Macrophage Activation Syndrome, Castleman Disease, and Hypereosinophilia," presentation on CD by David Fajgenbaum (Manchester Grand Hyatt San Diego, Grand Hall D)
4:00 - 5:30PM: ASH General Education Session: "Anxiety-Provoking Consults: Macrophage Activation Syndrome, Castleman Disease, and Hypereosinophilia," presentation on CD by David Fajgenbaum (Manchester Grand Hyatt San Diego, Grand Hall D)
6:15 - 8:15PM: ASH Poster Presentation: “PI3K/Akt/mTOR pathway activity is increased in lymph node tissue from idiopathic multicentric Castleman disease patients with TAFRO syndrome" (Session 203, Abstract# 1121, San Diego Convention Center, Hall GH)
6:30 - 7:30PM: CDCN's pre-Working Dinner Meeting: “Drinks and Data” poster session (Hard Rock Hotel, Legends 6) - see above to RSVP and/or submit abstracts
7:30 - 9:30PM: CDCN's 7th Annual “Accelerating Research & Treatments for Castleman Disease" Working Dinner Meeting (Hard Rock Hotel, Legends 6) - see above to RSVP
Sunday, December 2, 2018
6:00 - 8:00PM: ASH Poster Presentation: “Single-Cell RNA-Sequencing of Peripheral Blood Mononuclear Cells Reveals Changes in Immune Cell Composition and Distinct Inflammatory Gene Expression Profiles during Idiopathic Multicentric Castleman Disease Flare” (Session 203, Abstract# 2406, San Diego Convention Center, Hall GH)
6:00 - 8:00PM: ASH Poster Presentation: “Oligoclonal expansion of CD8+ T cells during idiopathic multicentric Castleman disease flares suggests an antigen driven process” (Session 203, Abstract# 2411, San Diego Convention Center, Hall GH)
Monday, December 3, 2018
6:00 - 8:00PM: ASH Poster Presentation: “Serum proteomics reveals distinct subtypes associated with treatment response in idiopathic multicentric Castleman disease” (Session 203, Abstract# 3716, San Diego Convention Center, Hall GH)
6:00 - 8:00PM: ASH Poster Presentation: "Hypercytokine-producing cells and oligoclonal T-cell populations in lymph nodes from Castleman disease patients" (Session 203, Abstract# 3725, San Diego Convention Center, Hall GH)
- 6:00 - 8:00PM: ASH Poster Presentation: "A Prospective Phase II Study of Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Idiopathic Multicentric Castleman's Disease" (Session 203, Abstract# 4142, San Diego Convention Center, Hall GH)
History: The CDCN held its first "Accelerating research & treatment for Castleman disease" meeting at the American Society of Hematology (ASH) 2012 meeting in Atlanta, GA. Thirty physicians, physician-scientists, and pharmaceutical partners from around the world joined us to share the latest discoveries around Castleman disease, which demonstrated clinician interest, determined initial priorities, and built tremendous momentum for the CDCN. Each year since, the CDCN's annual working dinner has been attended by more than 50 physicians and researchers, truly representing the incredible community of global experts dedicated to advancing the understanding and management of Castleman disease.
Abstracts from four posters presentated at last year's annual working dinner meeting in Atlanta, GA can be found below:
- Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes
- Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease
- Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach
- Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses
Sponsorship: Janssen Pharmaceuticals has generously sponsored this year's Working Dinner meeting! We are grateful for their support of the CD community.